Related Experiment Video
Updated: Jul 16, 2026
06:26
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
MASLD and the Cardiovascular-Kidney-Liver-Metabolic syndrome
Angeliki M Angelidi1,2, Chrysoula Boutari1, Michail Kokkorakis3,4
1Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Endocrine Reviews
|July 15, 2026
Summary
Obesity drives a spectrum of diseases, including type 2 diabetes and cardiovascular issues. Metabolic dysfunction-associated steatotic liver disease (MASLD) is now recognized as a key part of this cardio-kidney-liver-metabolic (CKLM) syndrome.
Area of Science:
- Cardiology
- Endocrinology
- Hepatology
- Nephrology
Background:
- Obesity is a global epidemic linked to type 2 diabetes, cardiovascular disease (CVD), metabolic syndrome, and chronic kidney disease (CKD).
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a significant factor in this cluster of conditions.
- These interconnected disorders are now conceptualized as cardio-kidney-liver-metabolic (CKLM) syndrome.
Purpose of the Study:
- To review the epidemiological, clinical, and research evidence on the associations between obesity, MASLD, and CKLM syndrome.
- To explore the complex interplay and shared pathophysiological mechanisms underlying these conditions.
- To highlight the clinical implications and therapeutic strategies for managing CKLM syndrome.
Main Methods:
- Narrative review of epidemiological studies.
- Synthesis of findings from clinical trials.
- Analysis of ongoing scientific research.
Main Results:
- Obesity, MASLD, and CKLM syndrome share significant pathophysiological links.
- The interplay between these conditions necessitates a holistic clinical approach.
- Effective management involves early detection, risk assessment, and multi-targeted interventions.
Conclusions:
- MASLD plays a crucial role in the CKLM syndrome spectrum.
- Integrated management strategies are essential for improving patient outcomes.
- Further research is needed to elucidate shared mechanisms and refine therapeutic approaches for the global burden of CKLM syndrome.
Related Concept Videos
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
01:24Nephrotic Syndrome I : Introduction
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...